A result before she leaves the clinic, no internet required
Each year, 350,000 women die of a disease that medicine already knows how to prevent — and nine in ten of those deaths fall on countries where screening barely exists. The Clinton Health Access Initiative is now offering $700,000 in catalytic funding to bring AI-powered cervical cancer screening tools to Africa, where coverage sits at roughly 4% against a WHO elimination target of 70%. It is a rare moment when a tractable technological solution, a willing funder, and an urgent human need arrive at the same threshold together.
- Cervical cancer kills 350,000 women a year, almost entirely in places where the disease could be caught and stopped — a preventable tragedy unfolding at scale.
- Sub-Saharan Africa screens only 4% of women, leaving the vast majority invisible to a health system that could save them with a single timely examination.
- AI tools running on smartphones have already shown they can detect precancerous lesions at nearly twice the rate of the naked-eye method, but they remain undeployed where they are needed most.
- The Clinton Health Access Initiative is offering milestone-based funding and demanding real-world validation, regulatory approval by 2027, and a credible multi-country scale-up plan within two years of launch.
- The application window closes June 9, 2026 — a narrow opening for innovators willing to meet rigorous standards in exchange for a chance to reshape cervical cancer outcomes across a continent.
Every year, cervical cancer claims roughly 350,000 lives — and nine out of ten of those deaths occur in low- and middle-income countries where the disease is almost entirely preventable. In sub-Saharan Africa, screening coverage hovers near 4%, while the WHO's 2030 elimination target requires reaching 70% of women twice in their lifetimes. No country in the region is close.
To close that gap, the Clinton Health Access Initiative has issued a request for proposals seeking partners to develop and commercialize AI-enabled cervical visual triage tools — software capable of running on a smartphone or tablet, offline, and delivering a result before the patient leaves the clinic. A frontline worker captures an image during a routine exam; the AI analyzes it on the spot. In a recent five-country study, this approach detected precancerous lesions at 60%, compared with 37% for traditional visual inspection.
The initiative is offering $700,000 in milestone-based funding, though co-investment is expected. Eligible applicants must have demonstrated experience in AI medical device development and deployment in resource-limited settings. The bar is high: tools must be validated in real-world clinical environments and on independent datasets, paired with a regulatory strategy targeting approval by end-2027, and supported by an affordable pricing model and a plan to scale across multiple countries within 24 months.
The initial focus is Africa, with possible expansion to Southeast Asia for applicants who can first establish a credible foothold on the continent. The deadline to apply is June 9, 2026 — a narrow window for innovators willing to meet demanding standards in pursuit of one of global health's most solvable tragedies.
Every year, cervical cancer kills roughly 350,000 women worldwide. Nine out of ten of those deaths happen in low- and middle-income countries—places where the disease is almost entirely preventable, yet screening coverage in sub-Saharan Africa hovers around 4%. The World Health Organization has set a target for elimination by 2030, which requires reaching 70% of women with a high-performance screening test, administered twice in their lifetimes. No country in the region is anywhere close.
This gap is what the Clinton Health Access Initiative is now trying to address. The organization has opened a request for proposals seeking partners to develop, validate, and bring to market AI-enabled cervical visual triage tools—software that can run on a smartphone or tablet and deliver screening results in real time, without requiring an internet connection. A frontline health worker captures an image of the cervix during a routine pelvic exam, the AI model analyzes it, and the patient receives a result before she leaves the clinic. In a recent five-country study, this approach detected precancerous lesions at a rate of 60.1%, compared with just 36.6% for the traditional method of visual inspection with acetic acid.
The Clinton Initiative is offering $700,000 in milestone-based funding to selected partners, though the organization expects this to cover only part of the total cost of development and commercialization. Co-investment is strongly encouraged. Eligible applicants are organizations with demonstrated experience in AI-enabled medical device development, regulatory approval, and deployment in resource-limited settings. Partnerships and consortiums are welcome. Prior experience in low- and middle-income countries is not strictly required, but applicants must show they can operate effectively in those contexts, either directly or through partners.
The expectations are substantial. The tool must work offline and deliver results at the point of care, in the same encounter. It must undergo prospective validation in real-world clinical settings, plus external validation on independent datasets—retrospective studies or single-site data will not be sufficient. Applicants must present a regulatory strategy aligned with international frameworks like the EU Medical Device Regulation or FDA pathways, with target approval by the end of 2027. And they must develop pricing models built for affordability and transparency, with a credible plan to scale across multiple countries within 24 months of market introduction.
The initial geographic focus is Africa, though applicants can propose expansion to other low- and middle-income regions, including Southeast Asia, if they can demonstrate a credible strategy for doing so after establishing themselves in Africa first. The deadline to apply is June 9, 2026. For digital health innovators working in resource-limited contexts, this represents a rare opportunity to tackle a disease that kills hundreds of thousands of preventable deaths each year—and to do it with the backing of a major global health funder.
Notable Quotes
The disease is almost entirely preventable, yet the average screening coverage in sub-Saharan Africa is around 4%— Clinton Health Access Initiative
The Hearth Conversation Another angle on the story
Why does cervical cancer screening coverage stay so low in sub-Saharan Africa when the disease is preventable?
The infrastructure isn't there. Screening requires trained personnel, equipment, and a system to follow up on results. In many places, there's no reliable way to do any of that. A smartphone-based tool removes some of those barriers—you don't need a lab, you don't need to send samples away, you get an answer immediately.
But if the technology works, why hasn't it already been deployed at scale?
Because getting a medical device approved and manufactured at scale costs millions of dollars. A startup or small organization can't do it alone. This funding is meant to bridge that gap—to take something that works in a study and turn it into something that actually reaches patients.
What makes this different from other screening approaches?
Speed and simplicity. Traditional visual inspection is subjective and misses lesions. This AI tool is consistent, it works offline, and the health worker gets a result while the patient is still there. That means no lost follow-up, no waiting for lab results.
Who's actually going to use this tool once it's approved?
Frontline health workers—nurses, midwives, community health officers—in clinics and health centers across Africa. The tool is designed for them, not for specialists. That's what makes scale possible.
What's the biggest risk in this approach?
Regulatory approval by end of 2027 is aggressive. And then you have to prove the tool actually works in messy real-world settings, not just in controlled studies. That's where many innovations fail.